Company Filing History:
2 out of 2 
1 out of 39 Years Active: 2022-2025
Title: Heechung Kwon: Innovator in Cancer Therapy
Introduction
Heechung Kwon is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of medical science, particularly in the development of innovative therapies for cancer treatment. With a total of 2 patents, his work focuses on utilizing recombinant herpes simplex viruses for targeted cancer therapies.
Latest Patents
Kwon's latest patents include groundbreaking inventions aimed at enhancing the efficacy of cancer treatments. The first patent describes a recombinant herpes simplex virus that has a modified glycoprotein gH for retargeting. This invention allows the virus to infect target cells that express a specific target molecule, making it a promising tool for anticancer therapy and gene therapy. The second patent involves a recombinant herpes simplex virus containing an expression cassette that expresses a fused protein of a cancer cell-targeting domain and the extracellular domain of HVEM. This innovation enables the virus to proliferate within cancer cells and release proteins that enhance the infection of surrounding cancer cells, thereby improving treatment outcomes.
Career Highlights
Heechung Kwon has worked with several prominent organizations throughout his career. He has been associated with Gencellmed Inc., where he contributed to the development of innovative medical solutions. Additionally, he has worked at the Korea Institute of Radiological & Medical Sciences, furthering his research in medical applications.
Collaborations
Kwon has collaborated with notable colleagues, including Hyunjung Baek and Hyun Yoo Joo. These partnerships have likely enriched his research and contributed to the advancements in his field.
Conclusion
Heechung Kwon's innovative work in the realm of cancer therapy through recombinant herpes simplex viruses showcases his dedication to improving medical treatments. His patents reflect a commitment to advancing science and providing new solutions for cancer patients.